Login
Companies $VCEL
$58.10 +$0.62 (1.08%) After hours
Vericel Corp logo

Vericel Corp

vcel.com

What Do They Do?

Sells cell-based cartilage treatments and burn-care products to hospitals and burn centers, serving orthopedic surgeons and burn-care teams.

How Do They Make Money?

MACI implants, kits and instruments account for most sales and are sold through specialty pharmacies or directly to facilities; Epicel is sold directly to hospitals and NexoBrid through specialty distributors. Most orders are due 30 to 90 days after delivery.

FY2025 revenue

Who Are Their Customers?

MACI reaches hospitals through specialty pharmacies or direct sales; Epicel is sold directly to hospitals and burn centers, while specialty distributors resell NexoBrid to those institutions.

Do Revenues Turn Into Profits?

Yes. It kept 6 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.

Operating income, FY2025
4% of revenue
▲ +144% vs FY2024 ($4.5M, 2%)
Net income, FY2025
6% of revenue
▲ +59% vs FY2024 ($10.4M, 4%)
Free cash flow, FY2025
9% of revenue
▲ Turned profitable vs FY2024 (−$5.8M, −2%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +26%
vs $67.5M in Q3 FY2025
Net income
▲ +179%
vs $5.1M in Q3 FY2025
  • Jul 30, 2026 Vericel raised its full-year revenue guidance It raised full-year revenue guidance to $330 to $340 million from $326 to $336 million.

Growing. Revenue grew 77% in 4 years, from $156.2M in FY2021 to $276.3M in FY2025, about 15% a year.

NexoBrid moves into commercial sales The earlier report expected U.S. commercial sales to begin; the latest describes NexoBrid as a marketed product covered by North American license and supply agreements.

Arthroscopic MACI moves from development to sale The earlier report described arthroscopic delivery as under development and awaiting label expansion; the latest reports approved instructions and commercially available instruments.

Who Do They Compete With?

Competes with Arthrex, Stryker, ConMed, Zimmer Biomet Holdings, Anika Therapeutics, CartiHeal, Smith & Nephew, Aesculap Biologics, Octane Medical Group, and Avita Medical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support